Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Would you offer adjuvant Abemciclib to ER positive HER2 negative with 1 LN positive, Ki-67 >20%, and low Oncotype?
Tumor 3 cm, grade 2 with Ki-67 25%
Answer from: Medical Oncologist at Community Practice
Yes. The low Oncotype DX RS should not alter the standard use of abemaciclib in this setting.
Sign in or Register to read more
17704
Related Questions
Are you offering chemotherapy for premenopausal patients with HR+ node positive breast CA with OncoType Dx scores of intermediate range of 11-25?
How long would you recommend a woman with HR+ node-positive breast cancer treated with surgery and chemotherapy during pregnancy can breastfeed, prior to starting adjuvant endocrine therapy?
What dose and formulation of GnRH agonist do you use for ovarian suppression in young breast cancer patients?
Would you recommend adjuvant abemaciclib for ER+ HER2 neg inflammatory breast cancer who do not achieve pCR with neoadjuvant chemotherapy?
Would you utilize Breast Cancer Index in patients with ER+ HER2+ breast cancer to guide whether or not to extend adjuvant endocrine therapy?
What is your cut off on ER percent positivity to treat them as functional triple negative cancer?
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
Do you modify your choice of systemic therapy for localized early stage ER+/PR+ HER2- breast if Mammaprint shows basal subtype?
What alternate neo-adjuvant backbone chemotherapy would you recommend in a patient with ER+ HER2+ clinical stage II breast CA with severe pan-colitis following a cycle of TCHP with docetaxel?